Literature DB >> 13052807

Quantitative studies of the virus-host relationship in chimpanzees after inapparent infection with Coxsackie viruses. I. The virus carrier state and the development of neutralizing antibodies.

J L MELNICK, A S KAPLAN.   

Abstract

Following oral administration of Coxsackie viruses (C viruses) to susceptible chimpanzees, these agents can be isolated from the throat for a period of approximately a week, from the blood for a few days, and from the stools for 2 to 3 weeks or even longer. Animals so infected respond with the formation of specific neutralizing antibodies which are maintained for at least 1 to 2 years. Such chimpanzees are immune when challenged orally with homologous strains of virus. They then excrete virus in the stools for 3 or 4 days (passive transfer); no virus can be recovered from the throats and blood of these animals, and neutralizing antibody levels remain unchanged. Animals immune to one antigenic type of C virus can be infected by feeding a different antigenic type. Following such a heterotypic challenge, virus can again be isolated from the throat, blood, and stools; neutralizing antibodies develop to the new strain. Antibodies to the Texas-1 type of C virus were already present in four chimpanzees upon their arrival in the laboratory from Africa. It was possible to set up intestinal carriage of the Texas-1 virus in these animals and to demonstrate a 10- to 100-fold increase in titer of neutralizing, as well as complement-fixing, antibody. Quantitative titrations of the amount of virus present in the stools and throat were performed. Immediately after the first feeding of virus relatively large amounts can be detected in the stools; the titer drops, but may be maintained for as long as 25 days at 10(-2) to 10(-3), furnishing evidence that virus multiplication has taken place. Virus in the throat reached the same order of magnitude at first as in the stools but there was a rapid decline to zero in a few days. The Ohio-1 virus differed from the others in that it persisted in the throat as long as in the stools, and in several instances reached a higher titer in the throat. Following homotypic challenge with all types, virus could be detected in the stools for only a relatively short period of time and at low concentration. Virus-neutralizing substances could not be detected in the stools or throat swabs of convalescent animals, at a time when their serum-neutralizing antibody titers were high. Under the limited conditions of the present experiments, C viruses had no effect on the infection of chimpanzees with three different antigenic types of poliomyelitis virus. Both poliomyelitis and C viruses set up independent infections without apparent interaction between them. No enhancement of the poliomyelitis infection took place, as was plain from the fact that none of the infected chimpanzees became paralyzed. a titration of Texas-1 C virus in four chimpanzees revealed that a suspension of infected tissue diluted to 10(6.0) could cause the development of the carrier state; accidental infection of control animals with other Coxsackie types indicated also that very little virus may be necessary to initiate infection. Seven distinct antigenic types of C virus were inoculated subcutaneously and intramuscularly at the same time into four chimpanzees. The response was the same as that following feeding; virus could be recovered from the throat, blood, and stools, and the animals developed neutralizing antibodies to all seven types of C virus. There was no detectable interference among the viruses. Cortisone did not bring about the reappearance of the virus excretion in chimpanzees previously infected and shown to be intestinal carriers of poliomyelitis and Coxsackie viruses.

Entities:  

Keywords:  COXSACKIE VIRUSES/infections

Mesh:

Substances:

Year:  1953        PMID: 13052807      PMCID: PMC2136268          DOI: 10.1084/jem.97.3.367

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  14 in total

1.  Identification of Coxsackie viruses by immunological methods and their classification into 16 antigenically distinct types.

Authors:  G CONTRERAS; V H BARNETT; J L MELNICK
Journal:  J Immunol       Date:  1952-10       Impact factor: 5.422

2.  Poliomyelitis virus in blood of orally infected monkeys and chimpanzees.

Authors:  D M HORSTMANN
Journal:  Proc Soc Exp Biol Med       Date:  1952-03

3.  Isolation from human sera in Egypt of a virus apparently identical to West Nile virus.

Authors:  J L MELNICK; J R PAUL; J T RIORDAN; V H BARNETT; N GOLDBLUM; E ZABIN
Journal:  Proc Soc Exp Biol Med       Date:  1951-08

4.  Serologic differences among strains of the Coxsackie group of viruses.

Authors:  G M SICKLES; G DALLDORF
Journal:  Proc Soc Exp Biol Med       Date:  1949-10

5.  A reconsideration of the pathogenesis of poliomyelitis.

Authors:  D BODIAN
Journal:  Am J Hyg       Date:  1952-05

6.  Quantitative studies of the virus-host relationship in chimpanzees after inapparent infection with Coxsackie viruses. II. The development of complement-fixing antibodies.

Authors:  L M KRAFT; J L MELNICK
Journal:  J Exp Med       Date:  1953-03       Impact factor: 14.307

7.  Pathogenesis of coxsackie virus infection; multiplication of virus and evolution of the muscle lesion in mice.

Authors:  J L MELNICK; G C GODMAN
Journal:  J Exp Med       Date:  1951-03       Impact factor: 14.307

8.  Immunological reactions of the Coxsackie viruses. I. The neutralization test; technic and application.

Authors:  J L MELNICK; N LEDINKO
Journal:  J Exp Med       Date:  1950-11-01       Impact factor: 14.307

9.  Immunological reactions of the Coxsackie viruses. III. Cross-protection tests in infant mice born of vaccinated mothers; transfer of immunity through the milk.

Authors:  J L MELNICK; N A CLARKE; L M KRAFT
Journal:  J Exp Med       Date:  1950-11-01       Impact factor: 14.307

10.  An epidemic of paralytic poliomyelitis characterized by dual infections with poliomyelitis and Coxsackie viruses.

Authors:  J L MELNICK; A S KAPLAN; E ZABIN; G CONTRERAS; N W LARKUM
Journal:  J Exp Med       Date:  1951-12-01       Impact factor: 14.307

View more
  10 in total

1.  Acute respiratory disease in normal volunteers associated with Coxsackie A-21 viral infection. III. Response to nasopharyngeal and enteric inoculation.

Authors:  A SPICKARD; H EVANS; V KNIGHT; K JOHNSON
Journal:  J Clin Invest       Date:  1963-06       Impact factor: 14.808

2.  Experimental infections with Coxsackie viruses. I. Studies on virulence and pathogenesis in Cynomolgus monkeys.

Authors:  H A WENNER; T Y LOU; P S KAMITSUKA
Journal:  Arch Gesamte Virusforsch       Date:  1961

3.  [Experimental animal studies on the neuropathogenicity of ECHO viruses types 4,6 and 16].

Authors:  H PETTE; G MAASS; L VALENCIANO; K MANNWEILER
Journal:  Klin Wochenschr       Date:  1960-09

4.  [Incidence of Coxsackie virus neutralizing antibodies in domestic animals].

Authors:  R BOSSE
Journal:  Z Hyg Infektionskr       Date:  1958

5.  Isolation of a Coxsackie virus during a summer outbreak of acute minor illness.

Authors:  J L MELNICK; M WALTON; I L MYERS
Journal:  Public Health Rep       Date:  1953-12       Impact factor: 2.792

Review 6.  Viral myocarditis. A review.

Authors:  J F Woodruff
Journal:  Am J Pathol       Date:  1980-11       Impact factor: 4.307

Review 7.  Comparative virology of primates.

Authors:  S S Kalter; R L Heberling
Journal:  Bacteriol Rev       Date:  1971-09

8.  Experimental oral immunization with L-forms of Vibrio cholerae.

Authors:  S C Agarwal; N K Ganguly
Journal:  Infect Immun       Date:  1972-01       Impact factor: 3.441

9.  Quantitative studies of the virus-host relationship in chimpanzees after inapparent infection with Coxsackie viruses. II. The development of complement-fixing antibodies.

Authors:  L M KRAFT; J L MELNICK
Journal:  J Exp Med       Date:  1953-03       Impact factor: 14.307

10.  The infection of chimpanzees with ECHO viruses.

Authors:  H ITOH; J L MELNICK
Journal:  J Exp Med       Date:  1957-11-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.